Neuroendocrine tumors of the digestive tract: Impact of new classifications and new agents on therapeutic approaches

Current Opinion in Oncology

Volumn 24, Issue 4, 2012, Pages 433-440

  Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

everolimus; sunitinib; targeted agents; WHO classification

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DALOTUZUMAB; ENDOSTATIN; EVEROLIMUS; FLUOROURACIL; GANITUMAB; GEFITINIB; MOTESANIB; OCTREOTIDE; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; VATALANIB;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CARCINOID SYNDROME; CLINICAL PRACTICE; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; NAUSEA; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; VOMITING; WORLD HEALTH ORGANIZATION;

CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 84862135843     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328353d7ba     Document Type: Review

References (47)

1. Bosman FT, Carneiro F. WHO Classification of Tumours, pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2010.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 2008; 26:3063-3072.
3. Lepage C, Rachet B, Coleman MP. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 2007; 132:899-904. (Pubitemid 46440869)
4. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395-401. (Pubitemid 44451313)
5. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451:757-762. (Pubitemid 47497934)
6. Sobin LH, Gospodarowicz M, Wittekind C. UICC International Union Against Cancer. TNM classification of malignant tumuors. 7th ed. Oxford: Wiley-Blackwell; 2010.
7. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011; 29:934-943.
8. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9:61-72.
9. Steinmuller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87:47-62. (Pubitemid 350308294)
10. Gurusamy KS, Pamecha V, Sharma D, Davidson BR. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev 2009; 1:CD007118.
11. Elias D, Goere D, Leroux G, et al. Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 2009; 35:1092-1097.
12. Saxena A, Chua TC, Sarkar A, et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery 2011; 149:209-220.
13. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26:2124-2130.
14. Cwikla JB, Sankowski A, Seklecka N, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol 2010; 21:787-794.
15. Pfeifer AK, Gregersen T, Gronbaek H, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 2011; 93:189-196.
16. Fjallskog ML, Ludvigsen E, Stridsberg M, et al. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003; 20:59-67. (Pubitemid 36344027)
17. Welin S, Fjallskog ML, Saras J, et al. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 2006; 84: 42-48. (Pubitemid 44973686)
18. Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncologica (Stockholm, Sweden) 1993; 32:107-114. (Pubitemid 23188522)
19. Wulbrand U, Wied M, Zofel P, et al. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Investig 1998; 28:1038-1049. (Pubitemid 29050140)
20. Nilsson O, Wangberg B, Theodorsson E, et al. Presence of IGF-I in human midgut carcinoid tumours-an autocrine regulator of carcinoid tumour growth? Int J Cancer 1992; 51:195-203.
21. Papouchado B, Erickson LA, Rohlinger AL, et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005; 18:1329-1335. (Pubitemid 41348651)
22. Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progressionfree survival among patients with low-grade neuroendocrine tumors. Cancer 2007; 109:1478-1486. (Pubitemid 46595681)
23. Srirajaskanthan R, Dancey G, Hackshaw A, et al. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. Endocr Relat Cancer 2009; 16:967-976.
24. Detjen KM, Rieke S, Deters A, et al. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res 2010; 16:420-429.
25. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28:245-255.
26. Kasajima A, Pavel M, Darb-Esfahani S, et al. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2011; 18:181-192.
27. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27:2278-2287.
28. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26:1316-1323.
29. Kulke MH. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. ASCO annual meeting abstract No 4044. 2006.
30. Kunz P, Kuo T, Zahn JM, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol 2010; 28 (Suppl 15): abstract 4104.
31. Venook AP, Ko AH, Tempero MA, et al. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol 2008; 26:(Suppl); abstract 15545.
32. Hobday TJ, Rubin J, Holen K, et al. Sorafenib MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 2007; 25(18 Pt 1):(Suppl); abstract 4504.
33. Castellano D, Capdevila J, Salazar R, et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumors Group (GETNE0801). J Clin Oncol 2011; 29:(Suppl); abstract 4113.
34. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26:3403-3410.
35. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New Engl J Med 2011; 364:501-513.
36. Phan A, Yao J, Fogelman DR, et al. A prospective, multiinstitutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010; 28 (15 Suppl); abstract 4001.
37. Hobday TJ, Holen K, Donehower R, et al. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. ASCO Annual Meeting Proceedings. 2006; 24 (18 Suppl); abstract 4043.
38. Reidy DL, Hollywood E, Segal M, Saltz L. A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well differentiated neuroendocrine tumors (NETs). J Clin Oncol 2010; 28(15 Suppl); abstract 4163.
39. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26:4311-4318.
40. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69-76.
41. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl J Med 2011; 364:514-523.
42. De Vries E, Anthony L, Sideris L, et al. Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results. J Clin Oncol 2011; 29:(Suppl); abstract 10624.
43. Pavel M, Hainsworth JD, Baudin E, et al. A randomized, double-blind, placebocontrolled multicenter phase III trial of everolimus +octreotide LAR vs. placebo +octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). J Clin Oncol 2010; 21:(Suppl 8): viii1-viii12, LBA18.
44. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. New Engl J Med 2009; 360:195-197.
45. Fiebrich HB, Siemerink EJ, Brouwers AH, et al. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist 2011; 16:783-787.
46. Ferrer-Garcia JC, Tolosa-Torrens M, Hernando-Melia C, et al. Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma. Endocr Pract 2011; 17:e17-e20.
47. Baudin E, Wolin E, Castellano D, et al. Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results. J Clin Oncol 2011; 29: (Suppl); abstract 10527.